in this issue
Pharma/fine chemicals roundup—4 June 2013
10:31 AM MDT | June 4, 2013 | By DEEPTI RAMESH
Dr. Reddy's and Fujifilm call off JV for generic drugs in Japan, to explore opportunities in APIs
Dr. Reddy’s Laboratories (Hyderabad, India) and Fujifilm (Tokyo) have decided to terminate their previously announced agreement for an exclusive partnership in the generic drugs business in the Japanese market via a joint venture in Japan, the companies announced. Dr. Reddy’s and Fujifilm signed an memorandum of understanding in July 2011 to establish a jv in Japan for manufacturing finished generic drugs for the Japanese market. It was agreed that Fujifilm would hold a 51% stake in the jv, and Dr. Reddy’s would hold the rest. The pharmaceutical services and active ingredients business of Dr. Reddy’s was to provide the active pharmaceutical ingredients (APIs) needed for the production of the finished drug products. The two companies will, however, continue to explore partnership/alliance opportunities in other pharmaceutical businesses, such as API development and manufacturing, contract R&D and manufacturing, and the development and marketing of super-generics.
ICIG announces new CordenPharma management team
Privately owned industrial holding company International Chemical Investors Group (ICIG) has announced changes in the management of CordenPharma, its pharmaceutical contract manufacturing business. Effective 1 June, CordenPharma will operate two business groups: active pharmaceutical ingredients (APIs) and drug products.
Christian Ewers, currently general manager of CordenPharma Switzerland, will assume the position of COO of the CordenPharma API business in addition to his current role. In his new role he will assume responsibility for both CordenPharma's proprietary APIs as well as custom manufacturing businesses. Karsten Benzing, currently executive principal at ICIG, will assume the position of COO of the CordenPharma drug product business.
CordenPharma is involved in the contract development and manufacturing of oral, sterile, highly potent, and antibiotic pharmaceutical drug products; their APIs; and associated packaging services, with total annual sales of €330 million ($429 million).
API business of Grindeks reports rise in sales
Pharmaceutical company Grindeks' (Riga, Latvia) active pharmaceutical ingredients (API) business reports a 27% rise in sales in the first quarter of 2013 compared with the first quarter of 2012, to 1.9 million lati ($3.5 million). Grindeks is the leading pharmaceutical company in the Baltic states and is involved in the research, development, manufacture, and sale of original products, generics, and APIs. The company’s main API export markets are Canada, Germany, Netherlands, and the United States. “The year 2013 is a challenging year in which the company more than ever has to take its opportunities in both the active pharmaceutical ingredients business, because an essential, all-industry influencing EU regulation will enter into force in July, and the final dosage forms business, where the protectionism to local manufacturers is increasing in important export countries,” says Juris Bundulis, chairman of the board of Grindeks.
CPhI announces founding members of expert industry panel
CPhI Worldwide has announced the founding members of its expert industry panel who are set to collectively assess the changes taking place across the industry in a series of monthly and annual reports—with the first monthly report on formulation and ingredients out in mid-June. The panel has already confirmed six full members including experts on active pharmaceutical ingredients (APIs) and excipients, Girish Malhorta and Brian Carlin, respectively. In addition, the panel features regulatory experts, Ajaz Hussain and Ali Afnan, the who is an expert on development processes. Ajaz Hussain, now part of Wockhardt, will lend his expertise in establishing and improving drug regulation. Across supply chain issues, the panel will leverage the knowledge of Hedley Rees, and Bikash Chatterjee will lend his expertise on quality systems and the Asian market. CPhI will bring in between 12 and 15 experts in total, covering the entire pharmaceutical supply chain from R&D through to finished products.
UPM Pharmaceuticals buys Pfizer plant at Bristol, TN
UPM Pharmaceuticals (Baltimore, MD) a drug development and contract manufacturer, says it will acquire Pfizer’s commercial manufacturing facility at Bristol, TN. The acquisition of the Pfizer facility will provide UPM with large scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules, as well as semi-solid manufacturing of creams and ointments. The facility will also provide for comprehensive tech transfer support, pilot plant scale-up capabilities, analytical and microbial testing, as well as dedicated suites for potent compounds. As part of the purchase, UPM will continue to manufacture Pfizer’s current portfolio of products within the facility for two years. The Pfizer facility was once home to King Pharmaceuticals (Bristol), which was acquired by Pfizer in 2010. King Pharmaceuticals was founded by UPM’s current chairman and CEO John Gregory.